CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Top Cited Papers
- 1 February 2006
- journal article
- review article
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 46 (1) , 101-122
- https://doi.org/10.1146/annurev.pharmtox.46.120604.141254
Abstract
▪ Abstract CB1 and CB2 cannabinoid receptors are the primary targets of endogenous cannabinoids (endocannabinoids). These G protein–coupled receptors play an important role in many processes, including metabolic regulation, craving, pain, anxiety, bone growth, and immune function. Cannabinoid receptors can be engaged directly by agonists or antagonists, or indirectly by manipulating endocannabinoid metabolism. In the past several years, it has become apparent from preclinical studies that therapies either directly or indirectly influencing cannabinoid receptors might be clinically useful. This review considers the components of the endocannabinoid system and discusses some of the most promising endocannabinoid-based therapies.Keywords
This publication has 140 references indexed in Scilit:
- Low dose oral cannabinoid therapy reduces progression of atherosclerosis in miceNature, 2005
- Anandamide transportPharmacology & Therapeutics, 2004
- Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonistBritish Journal of Pharmacology, 2004
- Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brainThe Journal of cell biology, 2003
- Cannabis and alcohol – a close friendshipTrends in Pharmacological Sciences, 2003
- Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain modelsEuropean Journal of Neuroscience, 2003
- Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B PathwayJournal of Biological Chemistry, 2002
- Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overviewProstaglandins, Leukotrienes & Essential Fatty Acids, 2002
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorPublished by Wiley ,2001
- Inhibition of macrophage nitric oxide production by tetrahydrocannabinol in vivo and in vitroInternational Journal of Immunopharmacology, 1996